Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: miyoshi y. Breast Cancer. 2024 May;31(3):536-538. doi: 10.1007/s12282-024-01552-y. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433180 No abstract available.
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y, Watanabe T, Hida AI, Higuchi T, Miyagawa Y, Ozawa H, Bun A, Fukui R, Sata A, Imamura M, Hirota S, Miyoshi Y. Fujimoto Y, et al. Among authors: miyoshi y. Breast Cancer. 2019 Nov;26(6):738-747. doi: 10.1007/s12282-019-00977-0. Epub 2019 May 16. Breast Cancer. 2019. PMID: 31098866
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: miyoshi y. Breast Cancer. 2023 Sep;30(5):703-713. doi: 10.1007/s12282-023-01462-5. Epub 2023 Apr 28. Breast Cancer. 2023. PMID: 37115435 Free PMC article.
Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, Inoue N, Ito T, Hirota S, Sasa M, Katagiri T, Fujimoto Y, Hatada T, Ichii S, Nishizaki T, Tomita N, Miyoshi Y. Murase K, et al. Among authors: miyoshi y. Breast Cancer. 2014 Jan;21(1):52-7. doi: 10.1007/s12282-012-0348-z. Epub 2012 Feb 23. Breast Cancer. 2014. PMID: 22359195
Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women.
Miyagawa Y, Miyake T, Yanai A, Murase K, Imamura M, Ichii S, Takatsuka Y, Ito T, Hirota S, Saito M, Kotoura Y, Miyauchi K, Fujimoto Y, Hatada T, Sasa M, Miyoshi Y. Miyagawa Y, et al. Among authors: miyoshi y. Breast Cancer. 2015 Jul;22(4):399-405. doi: 10.1007/s12282-013-0493-z. Epub 2013 Sep 3. Breast Cancer. 2015. PMID: 24000037
1,035 results